Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer

(2018) Yoshikane Yamauchi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

(2017) Etienne Giroux Leprieur et al.   EUROPEAN JOURNAL OF CANCER

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

(2017) Sun Hye Kim et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

(2017) Renee N. Donahue et al.   Journal for ImmunoTherapy of Cancer

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

(2016) P. F. Ferrucci et al.   ANNALS OF ONCOLOGY

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer

(2016) Raffaele Califano et al.   Current Oncology Reports

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

(2016) Rikke B. Holmgaard et al.   OncoImmunology

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

(2016) Claud Grigg et al.   Journal for ImmunoTherapy of Cancer

Unknown

(2016)   CANCER

Colorectal Cancer Survivorship Care Guidelines

(2015)   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Flow cytometric detection of circulating dendritic cells in healthy subjects

(2015) B Rovati et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

OMIP-017: Human CD4+helper T-cell subsets including follicular helper cells

(2013) Yolanda D. Mahnke et al.   CYTOMETRY PART A

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells

(2013) Amandine Legat et al.   Frontiers in Immunology

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A